Belgian PE firm Vendis Capital has invested in over-the-counter drugs producer Sylphar, taking over from Concordia Fund.
Sale ends a four-year holding period for Capvis Equity, which acquired the company in 2014
Firm saw its turnover double to €100m and the number of employees increase from 800 to 3,000
VC firm 50 Partners also takes part in the financing, as well as Blablacar CTO Francis Nappez
GP buys 20% of French aeronautics and automotive systems developer Vision Systems